Source: Ask the Secretary of the Board
Investor Question: The company shouldn’t continue to spend heavily on developing drugs with low incidence rates and no benefit, right? It should consider the next steps for normal survival and development.
Secretary’s Response (Changchun High & New Technology SZ000661): Thank you for your concern and suggestions. The company’s R&D investment…
Web link
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Investor Question: The company shouldn't spend large sums on developing ineffective drugs with low incidence rates anymore, right...
Source: Ask the Secretary of the Board
Investor Question: The company shouldn’t continue to spend heavily on developing drugs with low incidence rates and no benefit, right? It should consider the next steps for normal survival and development.
Secretary’s Response (Changchun High & New Technology SZ000661): Thank you for your concern and suggestions. The company’s R&D investment…
Web link